Metformin (100-500 mg/kg/d) treatment increases NO bioavailability and attenuates high-sensitivity CRP (hCRP)-induced hypertension by activating of AMPK/peroxisome proliferator-activated receptor δ (PPARδ) pathway 190 and AMPK-eNOS phosphorylation pathway 191 in animal studies. This evidence concerns the gene CRP and hypertensive disorder.